VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Activity
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

41 hedge funds and large institutions have $67.2M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 8 closing their positions.

Holders
41
Holders Change
+3
Holders Change %
+7.89%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
11
Increased
11
Reduced
6
Closed
8
Calls
$37.4M
Puts
$141K
Net Calls
+$37.3M
Net Calls Change
+$37.2M

Top Buyers

1
RCM
1
RA Capital Management
Massachusetts
$11.4M
2
EAM
2
Eventide Asset Management
Massachusetts
$8.36M
3
RPAM
3
Rhenman & Partners Asset Management
Sweden
$1.66M
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.74M
5
BC
5
Boxer Capital
California
$4.89M

Top Sellers

1
GPP
1
Great Point Partners
Connecticut
$0
2
SM
2
Sabby Management
Florida
$461K
3
SFM
3
Sphera Funds Management
Israel
$0
4
Wells Fargo
4
Wells Fargo
California
$171K
5
DCM
5
DAFNA Capital Management
California
$2.89M
Name Market Value Shares Shares
Change 		Shares
Change %
EA
51
Edge Advisors
Georgia
$0 33 +33 New
1 2
3